Supporting this finding, a study based on clinical data from a German breast cancer reported a pCR rate of 54.3% in BRCA1/2 mutation carriers versus 22.6% in noncarriers (adjusted odds ratio [OR] = 2.48, 95% confidence interval [CI] 1.26–4.91), with pCR emerging as the strongest predictor of both disease-free and overall survival, independent of BRCA 1/2 mutation status [31]. Here, BRCA1 is linked to breast carcinoma.